Exubera Success May Hinge on Usability
Ryan, who has a buy rating on Pfizer, said "many doctors" believe some patients will have trouble gauging their ideal dose when inhaling Exubera. The best potential customers will be "motivated patients who were new to insulin therapy," she said. Ryan doesn't own shares, but her firm has provided services to Pfizer.
Several researchers at the ADA convention pointed out that technology improves over time, and that's been the case for insulin administration. Where once big needles were used for injections, now there are much smaller devices and pumps. The first insulin pump was the size of a backpack. Now, they're as small as cell phone or pagers.
As for insulin inhalers, Pfizer and Nektar will be pressed to improve Exubera not only for greater patient convenience, but also because of competition. Several companies are testing devices resembling anything from a cell phone to an asthma inhaler. Some potential competitors appear to offer "sleeker devices and more convenient administration," Arnold says.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV